BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Aucatzyl (obecabtagene autoleucel) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Aucatzyl (obecabtagene autoleucel)\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06333483-10865@assetmemo.bio
DTSTAMP:20261121T010132Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Aucatzyl (obecabtagene autoleucel): Phase 1 readout est. (NCT063334
 83)
DESCRIPTION:Aucatzyl (obecabtagene autoleucel)\, phase 1.\nStudy: Obe-cel i
 n Adolescent [Applicable in UK Only] and Adult Severe\, Refractory Systemi
 c Lupus Erythematosus\nEstimated primary completion: September 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/obecabtagene-autoleucel#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063334
 83
URL:https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06173518-10865@assetmemo.bio
DTSTAMP:20261121T010132Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Aucatzyl (obecabtagene autoleucel): Phase 1 readout est. (NCT061735
 18)
DESCRIPTION:Aucatzyl (obecabtagene autoleucel)\, phase 1\, Acute Lymphoblas
 tic Leukemia.\nStudy: A Study of CD19 Targeted CAR T Cell Therapy in Pedia
 tric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leuke
 mia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)\nEst
 imated primary completion: November 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06173518
URL:https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07053059-10865@assetmemo.bio
DTSTAMP:20261121T010132Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Aucatzyl (obecabtagene autoleucel): Phase 2 readout est. (NCT070530
 59)
DESCRIPTION:Aucatzyl (obecabtagene autoleucel)\, phase 2.\nStudy: Phase 2 S
 tudy Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel
  as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acut
 e Lymphocytic Leukemia (ALL)\nEstimated primary completion: 31 May 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/obecabtagene-autoleuce
 l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 053059
URL:https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07053800-10865@assetmemo.bio
DTSTAMP:20261121T010132Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Aucatzyl (obecabtagene autoleucel): Phase 2 readout est. (NCT070538
 00)
DESCRIPTION:Aucatzyl (obecabtagene autoleucel)\, phase 2.\nStudy: Obe-cel i
 n Severe\, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus
  Nephritis (LN)\nEstimated primary completion: August 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07053800
URL:https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400029-10865@assetmemo.bio
DTSTAMP:20261121T010132Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Aucatzyl (obecabtagene autoleucel): Phase 2 readout est. (NCT074000
 29)
DESCRIPTION:Aucatzyl (obecabtagene autoleucel)\, phase 2\, Acute Lymphoblas
 tic Leukemia.\nStudy: A Study of Obecabtagene Autoleucel in People With B-
 cell Acute Lymphoblastic Leukemia\nEstimated primary completion: February 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/obecabtagene-au
 toleucel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07400029
URL:https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04404660-10865@assetmemo.bio
DTSTAMP:20261121T010132Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Aucatzyl (obecabtagene autoleucel): Phase 1/2 readout est. (NCT0440
 4660)
DESCRIPTION:Aucatzyl (obecabtagene autoleucel)\, phase 1/2\, Acute Lymphobl
 astic Leukemia.\nStudy: A Study of CD19 Targeted CAR T Cell Therapy in Adu
 lt Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaem
 ia (ALL)\nEstimated primary completion: 30 June 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04404660
URL:https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139743-10865@assetmemo.bio
DTSTAMP:20261121T010132Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:Aucatzyl (obecabtagene autoleucel): Phase 1 readout est. (NCT071397
 43)
DESCRIPTION:Aucatzyl (obecabtagene autoleucel)\, phase 1.\nStudy: Obe-cel i
 n Refractory Progressive Forms of Multiple Sclerosis\nEstimated primary co
 mpletion: 15 August 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/obecabtagene-autoleucel#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07139743
URL:https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
